3-amino-1-(4-methylpiperazin-1-yl)propan-1-one | 717904-35-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-amino-1-(4-methylpiperazin-1-yl)propan-1-one
• 英文别名: 1-(4-methylpiperazinyl)(2-aminoethyl)methanone
• CAS: 717904-35-3
• 化学式: C₈H₁₇N₃O
• mdl: MFCD04116807
• 分子量: 171.242
• InChiKey: HNWCTCGGYQCMQS-UHFFFAOYSA-N

物化性质

• 熔点：
  207-208°C

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4,7-二氯喹啉 、 3-amino-1-(4-methylpiperazin-1-yl)propan-1-one 以 苯酚 为溶剂， 以45%的产率得到3-(7-chloroquinolin-4-ylamino)-1-(4-methylpiperazin-1-yl)propan-1-one
  参考文献：
  名称：

  Antiplasmodial activity of new 4-aminoquinoline derivatives against chloroquine resistant strain

  摘要：

  Emergence and spread of multidrug resistant strains of Plasmodium falciparum has severely limited the antimalarial chemotherapeutic options. In order to overcome the obstacle, a set of new side-chain modified 4-aminoquinolines were synthesized and screened against chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of P. falciparum. The key feature of the designed molecules is the use of methylpiperazine linked α, β(3)- and γ-amino acids to generate novel side chain modified 4-aminoquinoline analogues. Among the evaluated compounds, 20c and 30 were found more potent than CQ against K1 and displayed a four-fold and a three-fold higher activity respectively, with a good selectivity index (SI=5846 and 11,350). All synthesized compounds had resistance index between 1.06 and >14.13 as against 47.2 for chloroquine. Biophysical studies suggested that this series of compounds act on heme polymerization target.

  DOI：

  10.1016/j.bmc.2014.05.024
• 作为产物：
  描述：

  N-[[3-(4-methylpiperazin-1-yl)-3-oxo]propyl]carbamic acid 1,1-dimethylethyl ester 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 3-amino-1-(4-methylpiperazin-1-yl)propan-1-one
  参考文献：
  名称：

  [EN] TRITERPENE AMINE DERIVATIVES
  [FR] DÉRIVÉS D'AMINE TRITERPÉNIQUE

  摘要：

  本发明涉及新型具有药用活性的三萜胺衍生物，含有这些衍生物的药物组合物，它们作为药物的用途，以及用这些化合物制造特定药物的用途。本发明还涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉

  公开号：

  WO2020006510A1

文献信息

• CHEMICAL COMPOUNDS-821
  申请人：Finlay Maurice Raymond

  公开号：US20090048269A1

  公开（公告）日：2009-02-19

  The invention relates to chemical compounds of the formula (I), or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβR1) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal such as man.

  该发明涉及化学式(I)的化合物，或其药学上可接受的盐，具有ALK5（TGFβR1）抑制活性，因此在抗癌活性方面有用，从而在治疗人体或动物体的方法中有用。该发明还涉及制造上述化学化合物的方法，含有它们的药物组合物，以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。
• Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
  申请人：SUGEN, Inc.

  公开号：US20040186160A1

  公开（公告）日：2004-09-23

  The present invention is directed to a class indolinone compounds, hexahydro-cyclohepta-pyrrole oxindoles, which are useful as protein kinase inhibitors.

  本发明涉及一类吲哚酮化合物，即六氢-环庚-吡咯酮氧吲哚，其作为蛋白激酶抑制剂具有用途。
• [EN] ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013092574A1

  公开（公告）日：2013-06-27

  The present invention relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代异噻唑并[5,4-b]吡啶-2-羧酰胺，其中R1、R2、R3、R10、R11和X如权利要求中所定义。式I的化合物是转谷氨酰胺酶抑制剂，特别是转谷氨酰胺酶2（TGM2）的抑制剂，并适用于治疗各种疾病，例如退行性关节疾病如骨关节炎。本发明还涉及制备式I的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• [EN] TRITERPENE AMINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINE TRITERPÉNIQUE
  申请人：DFH THERAPEUTICS

  公开号：WO2020006510A1

  公开（公告）日：2020-01-02

  The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).

  本发明涉及新型具有药用活性的三萜胺衍生物，含有这些衍生物的药物组合物，它们作为药物的用途，以及用这些化合物制造特定药物的用途。本发明还涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉及涉
• [EN] INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PROTÉINES KINASES
  申请人：RESPIVERT LTD

  公开号：WO2017153748A1

  公开（公告）日：2017-09-14

  The present invention relates inter alia to a compound of formula (I) wherein R1, R2 and R3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.

  本发明涉及公式（I）中的化合物，其中R1、R2和R3如规范中定义的那样，以及包含相同化合物的组合物，以及化合物的使用以及化合物组合物的治疗，例如在治疗纤维化疾病或间质性肺部疾病中的应用，特别是特发性肺纤维化。